NMR systems and methods for the rapid detection of analytes
First Claim
Patent Images
1. A composition comprising:
- (a) a liquid sample containing an analyte; and
(b) within the liquid sample from 1×
106 to 1×
1013 magnetic particles per milliliter of the liquid sample, the magnetic particles having a mean diameter of from 700 nm to 950 nm, a T2 relaxivity per particle of from 1×
104 to 1×
1012 and binding moieties specific to the analyte are conjugated to their surface,wherein the analyte from the sample is bound to at least one of the binding moieties on at least one magnetic particle.
2 Assignments
0 Petitions
Accused Products
Abstract
This invention features systems and methods for the detection of analytes, and their use in the treatment and diagnosis of disease.
-
Citations
19 Claims
-
1. A composition comprising:
-
(a) a liquid sample containing an analyte; and (b) within the liquid sample from 1×
106 to 1×
1013 magnetic particles per milliliter of the liquid sample, the magnetic particles having a mean diameter of from 700 nm to 950 nm, a T2 relaxivity per particle of from 1×
104 to 1×
1012 and binding moieties specific to the analyte are conjugated to their surface,wherein the analyte from the sample is bound to at least one of the binding moieties on at least one magnetic particle.
-
-
2. A composition comprising:
-
(a) a liquid sample suspected of containing a Candida nucleic acid; and (b) within the liquid sample from 1×
106 to 1×
1013 magnetic particles per milliliter of the liquid sample, the magnetic particles having a mean diameter of from 700 nm to 950 nm, a T2 relaxivity per particle of from 1×
109 to 1×
1012 mM−
1s−
1, and having a first nucleic acid probe and a second nucleic acid probe conjugated to their surface selected so that the first nucleic acid probe is operative to bind to a first segment of the Candida nucleic acid and the second nucleic acid probe is operative to bind to a second segment of the Candida nucleic acid. - View Dependent Claims (3)
-
-
4. A composition, comprising:
-
(a) a liquid sample containing one or more nucleic acid amplicons generated from an amplification reaction; and (b) within the liquid sample from 1×
106 to 1×
1013 magnetic particles per milliliter of the liquid sample, the magnetic particles having a mean diameter of from 700 nm to 950 nm, a T2 relaxivity per particle of from 1×
104 to 1×
1012 mM−
1s−
1, and having a first nucleic acid probe and a second nucleic acid probe conjugated to their surface selected so that the first nucleic acid probe is operative to bind to a first segment of the nucleic acid amplicons and the second nucleic acid probe is operative to bind to a second segment of the nucleic acid amplicons.
-
-
5. A composition, comprising:
-
(a) a liquid sample containing Candida nucleic acid amplicons generated from an amplification reaction; and (b) within the liquid sample from 1×
106 to 1×
1013 magnetic particles per milliliter of the liquid sample, the magnetic particles having a mean diameter of from 700 nm to 950 nm, a T2 relaxivity per particle of from 1×
104 to 1×
1012 mM−
1s−
1, and having a first nucleic acid probe and a second nucleic acid probe conjugated to their surface selected so that the first nucleic acid probe is operative to bind to a first segment of the Candida nucleic acid amplicons and the second nucleic acid probe is operative to bind to a second segment of the Candida nucleic acid amplicons. - View Dependent Claims (6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
-
17. A composition comprising:
-
(a) a liquid sample containing nucleic acid amplicons generated from an amplification reaction; (b) within the liquid sample from 1×
106 to 1×
1013 magnetic particles per milliliter of the liquid sample, the magnetic particles having a mean diameter of from 700 nm to 950 nm, a T2 relaxivity per particle of from 1×
104 to 1×
1012 mM−
1s−
1, and having a first nucleic acid probe and a second nucleic acid probe conjugated to their surface and selected to hybridize to a first segment and a second segment of the nucleic acid amplicons to form aggregates, the aggregates comprising the magnetic particles and the nucleic acid amplicons. - View Dependent Claims (18)
-
-
19. A method of detecting the presence of an analyte, comprising:
-
(a) combining a liquid sample containing an analyte with a population of 1×
106 to 1×
1013 magnetic particles per milliliter of the liquid sample, the magnetic particles having a mean diameter of from 700 nm to 950 nm, a T2 relaxivity per particle of from 1×
104 to 1×
1012 mM−
1s−
1, and binding moieties specific to a first binding site on the analyte are conjugated to their surface;(b) exposing the sample to a magnetic field to capture or concentrate the magnetic particles and the analyte; (c) exposing the concentrated magnetic particles to a surface derivatized with ligands complementary to a second binding site on the analyte thereby forming magnetic particle-analyte-ligand complexes; (d) placing the analyte-bound magnetic particles in a well having an radiofrequency (RF) coil disposed about the well, the RF coil configured to detect a signal produced by exposing the liquid sample to a bias magnetic field created using one or more magnets and an RF pulse sequence; (e) exposing the sample to a bias magnetic field and an RF pulse sequence; (f) following step (e), measuring the T2 relaxation signal; and (g) wherein an increase in T2 relaxation measured in step (f) indicates the presence of said analyte in the liquid sample.
-
Specification